Welcome to our dedicated page for Blade Air Mobility SEC filings (Ticker: BLDE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to decode Blade Air Mobility’s blend of life-saving organ transport and passenger helicopter routes? Start here. Our platform walks you through every SEC disclosure, from the first 8-K on a new hospital contract to the footnotes about Electric Vertical Aircraft in the annual report.
Use the search bar or follow the quick links below to jump directly to a Blade Air Mobility quarterly earnings report 10-Q filing or skim the Blade Air Mobility annual report 10-K simplified. Each document arrives within seconds of hitting EDGAR, accompanied by AI-powered summaries that highlight Medical-segment margins, passenger load factors, and fleet-transition costs—no accounting background required.
- Need real-time alerts? Track Blade Air Mobility Form 4 insider transactions real-time and spot buying or selling trends among directors.
- Review governance details in the Blade Air Mobility proxy statement executive compensation without wading through tables.
- Stay on top of Blade Air Mobility 8-K material events explained—from new transplant-center partnerships to aircraft supplier updates.
Common questions like “Blade Air Mobility insider trading Form 4 transactions” or “understanding Blade Air Mobility SEC documents with AI” are answered directly inside each filing card. Our AI pinpoints the revenue mix for every quarter, flags unusual related-party deals, and compares pay packages—all while keeping the full text a click away.
Whether you’re seeking a concise Blade Air Mobility earnings report filing analysis or verifying Blade Air Mobility executive stock transactions Form 4, our coverage ensures you won’t miss a detail. Complex aviation logistics just became readable.
CFO William A. Heyburn reported three transactions in Blade Air Mobility (BLDE) stock. On 08/01/2025 he received 139,286 Class A shares after the Compensation Committee certified that 2024 performance targets tied to previously granted PSUs had been achieved. To satisfy related tax obligations, the company withheld 76,177 shares at $3.99.
Following the vesting, Heyburn beneficially owned 1,463,940 shares. On 08/04/2025, acting under a pre-arranged Rule 10b5-1 plan dated 11/25/2024, he sold 46,918 shares at a weighted-average price of $4.94-$4.96, trimming his stake to 1,340,845 shares. The sale represents roughly 3 % of his current holdings and generated about $232k in gross proceeds. Net of all reported moves, Heyburn’s ownership increased by approximately 16 k shares, or +1 %.
No options or other derivative securities were transacted, and no additional insider participants were listed. Overall, the filing reflects routine equity compensation vesting combined with a modest, pre-scheduled liquidity sale, leaving the CFO with a substantial position aligned with shareholders.
Blade Air Mobility (NASDAQ: BLDE) Q2 2025 10-Q highlights
- Revenue rose 4% YoY to $70.8 m; Medical segment up 18% to $45.1 m, offsetting a 13% Passenger decline to $25.7 m.
- Cost discipline: Total operating expenses fell 5% to $75.8 m, driven by a 20% reduction in G&A and 32% lower selling & marketing spend.
- Profitability improving: Operating loss narrowed to $(5.0) m from $(12.1) m; net loss trimmed to $(3.7) m (-$0.05/sh) versus $(11.3) m (-$0.15/sh) prior-year.
- Segment Adjusted EBITDA grew 34% to $8.4 m; Medical contributed $6.0 m.
- Liquidity: Cash & equivalents $58.8 m plus $54.7 m short-term Treasuries; operating cash burn cut to $3.3 m (vs $7.1 m).
- Balance sheet: Warrant liability marked down to $3.0 m (from $5.8 m); goodwill now $44.3 m after organ-transport acquisitions.
- Share count: 81.7 m shares outstanding, up 2.3 m YTD due to equity compensation; stock-based comp $9.6 m YTD.
- Subsequent event: 1 Aug 25 agreement to sell Passenger business to Joby Aviation for up to $125 m ($90 m at close, $35 m earn-out, cash or JOBY stock). Transaction expected to be treated as discontinued operations.
- Guidance: none provided; management notes seasonality with stronger Q2–Q3 passenger demand.
Key takeaways: Blade is pivoting toward its higher-margin Medical segment while monetizing the Passenger operation. Liquidity remains solid and losses are shrinking, but execution risk on the Joby deal and continued passenger softness warrant monitoring.
FAQ
What is the current stock price of Blade Air Mobility (BLDE)?
What is the market cap of Blade Air Mobility (BLDE)?
